Health Care

Viridian Therapeutics Inc. (NASDAQ:VRDN) shares fell sharply Monday following topline Phase 3 data from Amgen Inc. (NASDAQ:AMGN) for TEPEZZA in thyroid eye disease (TED), intensifying competitive pressure in the space. Amgen Data Raises Competitive Pressure The Phase 3 TEPEZZA OBI trial met its...

Denali Therapeutics (NASDAQ:DNLI) shares are down on Monday as the company announced it has regained full rights to its investigational therapy DNL593 from Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) Takeda Ends Drug Partnership For Strategic Reasons Takeda on Friday notified Denali Therapeutics...

ImmunityBio Inc (NASDAQ:IBRX) shares were up during Monday’s premarket session, but dipped as the company addresses compliance issues raised by the U.S. Food and Drug Administration (FDA). The FDA issued a warning to ImmunityBio, alleging that the company made unsupported claims that Anktiva...

Amgen Inc. (NASDAQ:AMGN) shares are down on Monday after the company announced topline results from a Phase 3 trial of TEPEZZA, which is administered via an on-body injector for patients with moderate-to-severe active Thyroid Eye Disease. Trial Meets Primary Endpoint The Phase 3 TEPEZZA OBI trial...

Lipocine Inc. (NASDAQ:LPCN) shares are up during Monday’s premarket session after the company’s stock plunged almost 78% on Thursday following disappointing trial data. On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression...

Curanex Pharmaceuticals Inc. (NASDAQ:CURX) on Monday said that a recent patient case study may reinforce its strategic push into cancer cachexia, a severe wasting condition tied to advanced cancers with limited treatment options. Last week, Curanex added a new core indication, cancer cachexia, to...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares are down during Monday’s premarket session. The company announced plans to acquire Soleno Therapeutics Inc. (NASDAQ:SLNO) for $53.00 per share in cash, totaling approximately $2.9 billion. The company plans to finance the transaction using cash...

Medicus Pharma Ltd. (NASDAQ:MDCX) said Monday it has submitted an optimized Phase 2 study design to the U.S. Food and Drug Administration under its existing Investigational New Drug application for Teverelix. It is an investigational therapy targeting benign prostatic hyperplasia-related...

Health and Human Services Secretary Robert F. Kennedy Jr. is launching a targeted midterm campaign tour. He is highlighting popular "Make America Healthy Again" initiatives, including food dye removal, improvements in childhood nutrition and reductions in healthcare costs, while deliberately...

Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds New Focus The company's pipeline currently encompasses six core indications, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty...

The Trump administration is reportedly preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House. The announcement could come as soon as Thursday, Bloomberg reported, citing people familiar with the matter. The tariffs stem from a...

The Chinese biotech set up a separate "NewCo" company for its autoimmune drug, beating the likely proceeds from a conventional out-licensing deal image credit: Bamboo Works Key Takeaways: International drug rights were transferred to the new U.S.-based entity for an upfront fee and equity stake...

Visionary Holdings (NASDAQ:GV) shares surged 35.8% after hours to $0.28 Wednesday after the Toronto-based company announced a US$20 million investment cooperation agreement with Qingdao Xihai Rongke on Tuesday for an anti-aging project in China. Qingdao Xihai Rongke serves as both a strategic...

Structure Therapeutics Inc(NASDAQ:GPCR) shares are up on Wednesday, probably in reaction to the U.S. Food and Drug Administration (FDA) approval of a similar drug for obesity. • What’s the outlook for GCPR shares? FDA Approves Eli Lilly's Oral Weight Loss On Wednesday, the FDA approved...

Pfizer Inc (NYSE:PFE) and its German COVID-19 vaccine partner BioNTech SE (NASDAQ:BNTX) have reportedly halted recruitment for a large U.S. trial of their updated COVID-19 vaccine targeting adults aged 50 to 64, citing difficulty in enrolling enough participants. The companies confirmed they had...